About BioTelemetry (NASDAQ:BEAT)
BioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment's principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company's research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Laboratories & Research
- Sub-Industry: N/A
- Symbol: NASDAQ:BEAT
- CUSIP: N/A
- Web: www.gobio.com
Capitalization:- Market Cap: $1.0064 billion
- Outstanding Shares: 32,360,000
Average Prices:- 50 Day Moving Avg: $33.56
- 200 Day Moving Avg: $32.27
- 52 Week Range: $15.25 - $39.20
P/E:- Trailing P/E Ratio: 20.91
- Foreward P/E Ratio: 21.34
- P/E Growth: 1.48
Sales & Book Value:- Annual Revenue: $211.19 million
- Price / Sales: 4.77
- Book Value: $5.11 per share
- Price / Book: 6.10
Profitability:- EBITDA: $41.34 million
- Net Margins: 21.03%
- Return on Equity: 18.75%
- Return on Assets: 12.70%
Debt:- Debt-to-Equity Ratio: 0.16%
- Current Ratio: 2.03%
- Quick Ratio: 1.91%
Misc:- Average Volume: 508,303 shs.
- Beta: 0.68
- Short Ratio: 5.72
Frequently Asked Questions for BioTelemetry (NASDAQ:BEAT)
What is BioTelemetry's stock symbol?
BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."
How were BioTelemetry's earnings last quarter?
BioTelemetry, Inc. (NASDAQ:BEAT) announced its quarterly earnings results on Tuesday, August, 8th. The company reported $0.23 EPS for the quarter, beating the Zacks' consensus estimate of $0.21 by $0.02. The company had revenue of $58.10 million for the quarter, compared to analysts' expectations of $58.39 million. BioTelemetry had a net margin of 21.03% and a return on equity of 18.75%. BioTelemetry's revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.20 EPS. View BioTelemetry's Earnings History.
Where is BioTelemetry's stock going? Where will BioTelemetry's stock price be in 2017?
6 brokerages have issued 12 month price targets for BioTelemetry's stock. Their predictions range from $40.00 to $50.00. On average, they expect BioTelemetry's share price to reach $45.75 in the next twelve months. View Analyst Ratings for BioTelemetry.
Who are some of BioTelemetry's key competitors?
Some companies that are related to BioTelemetry include Inogen (INGN), Omnicell (OMCL), Brookdale Senior Living (BKD), Teladoc (TDOC), NxStage Medical (NXTM), Endo International PLC (ENDP), Theravance Biopharma (TBPH), Owens & Minor (OMI), Cambrex Corporation (CBM), Amedisys (AMED), Intercept Pharmaceuticals (ICPT), Emergent Biosolutions (EBS), Acceleron Pharma (XLRN), Immunomedics (IMMU), NovoCure Limited (NVCR), HMS Holdings Corp (HMSY), Healthways (TVTY) and Spectrum Pharmaceuticals (SPPI).
Who owns BioTelemetry stock?
BioTelemetry's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Summit Creek Advisors LLC (1.05%), Curbstone Financial Management Corp (0.07%), LS Investment Advisors LLC (0.03%) and Winslow Evans & Crocker Inc. (0.01%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, George Hrenko, Heather C Getz, Joseph H Capper, Peter Ferola and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry.
Who sold BioTelemetry stock? Who is selling BioTelemetry stock?
BioTelemetry's stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC. Company insiders that have sold BioTelemetry stock in the last year include Fred Broadway, George Hrenko and Robert J Rubin. View Insider Buying and Selling for BioTelemetry.
Who bought BioTelemetry stock? Who is buying BioTelemetry stock?
BioTelemetry's stock was acquired by a variety of institutional investors in the last quarter, including Curbstone Financial Management Corp, Winslow Evans & Crocker Inc. and LS Investment Advisors LLC. View Insider Buying and Selling for BioTelemetry.
How do I buy BioTelemetry stock?
Shares of BioTelemetry can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioTelemetry's stock price today?
One share of BioTelemetry stock can currently be purchased for approximately $31.15.
MarketBeat Community Rating for BioTelemetry (NASDAQ BEAT)MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for BioTelemetry (NASDAQ:BEAT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 5 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $45.75 (46.87% upside) |
Consensus Price Target History for BioTelemetry (NASDAQ:BEAT)
Analysts' Ratings History for BioTelemetry (NASDAQ:BEAT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/15/2017 | Off Wall Street | Initiated Coverage | Sell | | Medium |  |
| 8/10/2017 | Sidoti | Reiterated Rating | Buy | $42.00 -> $49.00 | Low | |
| 8/9/2017 | Dougherty & Co | Boost Price Target | Buy | $37.00 -> $40.00 | High | |
| 7/19/2017 | Benchmark Co. | Boost Price Target | Buy -> Buy | $38.00 -> $44.00 | Low | |
| 7/14/2017 | Lake Street Capital | Reiterated Rating | Buy | $35.00 -> $50.00 | High | |
| 12/13/2016 | Gabelli | Reiterated Rating | Buy | | N/A | |
(Data available from 10/21/2015 forward)
Earnings History for BioTelemetry (NASDAQ:BEAT)Earnings History by Quarter for BioTelemetry (NASDAQ BEAT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/8/2017 | Q2 2017 | $0.21 | $0.23 | $58.39 million | $58.10 million | View | Listen | |
| 5/3/2017 | Q1 2017 | $0.14 | $0.16 | $55.11 million | $55.88 million | View | Listen | |
| 2/22/2017 | Q4 2016 | $0.18 | $0.23 | $53.75 million | $53.96 million | View | Listen | |
| 11/2/2016 | Q316 | $0.18 | $0.21 | $52.92 million | $53.10 million | View | N/A | |
| 8/2/2016 | Q2 | $0.17 | $0.20 | $50.27 million | $52.68 million | View | Listen | |
| 4/26/2016 | Q1 | $0.10 | $0.20 | $46.54 million | $48.60 million | View | Listen | |
| 2/17/2016 | Q415 | $0.11 | $0.15 | $45.89 million | $46.70 million | View | Listen | |
| 11/9/2015 | Q3 | $0.11 | $0.13 | $46.05 million | $43.49 million | View | N/A | |
| 8/6/2015 | Q2 | $0.09 | $0.12 | $45.75 million | $44.81 million | View | Listen | |
| 5/6/2015 | Q115 | $0.02 | $0.06 | $43.80 million | $43.40 million | View | Listen | |
| 2/19/2015 | Q414 | $0.06 | $0.05 | $43.40 million | $43.70 million | View | Listen | |
| 10/30/2014 | Q214 | $0.01 | $0.06 | $42.00 million | $43.00 million | View | Listen | |
| 7/31/2014 | Q114 | $0.01 | $0.02 | $40.95 million | $42.70 million | View | Listen | |
| 5/6/2014 | Q413 | ($0.02) | ($0.04) | $38.40 million | $37.16 million | View | Listen | |
| 2/26/2014 | Q313 | ($0.04) | $0.05 | $32.26 million | $33.10 million | View | Listen | |
| 11/5/2013 | | ($0.05) | ($0.12) | $32.79 million | $31.90 million | View | Listen | |
| 7/30/2013 | Q2 2013 | | $0.02 | $27.50 million | $32.10 million | View | Listen | |
| 2/13/2013 | Q4 2012 | | ($0.09) | $26.80 million | $30.00 million | View | Listen | |
| 11/5/2012 | Q312 | ($0.09) | ($0.08) | $26.49 million | $27.00 million | View | N/A | |
| 8/8/2012 | | ($0.04) | ($0.01) | | | View | N/A | |
| 5/8/2012 | | ($0.12) | ($0.10) | | | View | N/A | |
| 2/22/2012 | | ($0.13) | ($0.04) | | | View | N/A | |
| 11/8/2011 | | ($0.09) | ($0.21) | | | View | N/A | |
| 8/8/2011 | | ($0.06) | ($0.05) | | | View | N/A | |
| 5/3/2011 | | ($0.15) | ($0.02) | | | View | N/A | |
| 2/17/2011 | | ($0.16) | ($0.13) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for BioTelemetry (NASDAQ:BEAT)2017 EPS Consensus Estimate: $0.86
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | $0.20 | $0.20 | $0.20 |
| Q2 2017 | 1 | $0.20 | $0.20 | $0.20 |
| Q3 2017 | 2 | $0.19 | $0.28 | $0.24 |
| Q4 2017 | 1 | $0.22 | $0.22 | $0.22 |
(Data provided by Zacks Investment Research)
Dividend History for BioTelemetry (NASDAQ:BEAT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for BioTelemetry (NASDAQ:BEAT)Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 77.67%
Insider Trades by Quarter for BioTelemetry (NASDAQ:BEAT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/15/2017 | Robert J. Rubin | Director | Sell | 15,000 | $28.14 | $422,100.00 | |
| 3/20/2017 | Fred Broadway | SVP | Sell | 3,429 | $26.90 | $92,240.10 | |
| 2/27/2017 | George Hrenko | SVP | Sell | 126,043 | $25.95 | $3,270,815.85 | |
| 2/21/2017 | Fred Broadway | SVP | Sell | 8,070 | $24.81 | $200,216.70 | |
| 9/19/2016 | George Hrenko | SVP | Sell | 1,061 | $18.50 | $19,628.50 | |
| 9/13/2016 | Heather C Getz | CFO | Sell | 5,866 | $18.23 | $106,937.18 | |
| 9/13/2016 | Joseph H Capper | Insider | Sell | 26,847 | $18.23 | $489,420.81 | |
| 9/13/2016 | Peter Ferola | General Counsel | Sell | 4,352 | $18.23 | $79,336.96 | |
| 9/9/2016 | Fred Broadway | SVP | Sell | 3,146 | $17.84 | $56,124.64 | |
| 9/8/2016 | George Hrenko | SVP | Sell | 3,491 | $18.06 | $63,047.46 | |
| 9/8/2016 | Heather C Getz | CFO | Sell | 2,979 | $18.10 | $53,919.90 | |
| 9/8/2016 | Joseph H Capper | Insider | Sell | 13,632 | $18.10 | $246,739.20 | |
| 9/8/2016 | Peter Ferola | General Counsel | Sell | 2,210 | $18.10 | $40,001.00 | |
| 9/7/2016 | Daniel Wisniewski | SVP | Sell | 9,225 | $18.51 | $170,754.75 | |
| 9/7/2016 | Heather C Getz | CFO | Sell | 18,945 | $18.52 | $350,861.40 | |
| 9/7/2016 | Joseph H Capper | Insider | Sell | 86,681 | $18.52 | $1,605,332.12 | |
| 9/7/2016 | Peter Ferola | General Counsel | Sell | 14,053 | $18.52 | $260,261.56 | |
| 9/6/2016 | Fred Broadway | SVP | Sell | 4,662 | $18.28 | $85,221.36 | |
| 9/6/2016 | Heather C Getz | CFO | Sell | 6,686 | $18.29 | $122,286.94 | |
| 9/6/2016 | Joseph H Capper | CEO | Sell | 30,595 | $18.29 | $559,582.55 | |
| 9/6/2016 | Peter Ferola | General Counsel | Sell | 4,960 | $18.29 | $90,718.40 | |
| 9/2/2016 | Fred Broadway | SVP | Sell | 4,466 | $18.75 | $83,737.50 | |
| 9/2/2016 | Heather C Getz | CFO | Sell | 6,547 | $18.75 | $122,756.25 | |
| 9/2/2016 | Joseph H Capper | CEO | Sell | 29,953 | $18.75 | $561,618.75 | |
| 9/2/2016 | Peter Ferola | General Counsel | Sell | 4,856 | $18.75 | $91,050.00 | |
| 9/1/2016 | Fred Broadway | SVP | Sell | 7,525 | $19.25 | $144,856.25 | |
| 9/1/2016 | Heather C Getz | CFO | Sell | 10,408 | $18.59 | $193,484.72 | |
| 9/1/2016 | Joseph H Capper | Insider | Sell | 47,622 | $18.59 | $885,292.98 | |
| 9/1/2016 | Peter Ferola | General Counsel | Sell | 7,722 | $18.59 | $143,551.98 | |
| 8/30/2016 | Fred Broadway | SVP | Sell | 12,121 | $19.07 | $231,147.47 | |
| 8/30/2016 | Heather C Getz | CFO | Sell | 17,482 | $19.07 | $333,381.74 | |
| 8/30/2016 | Joseph H Capper | Insider | Sell | 79,986 | $19.07 | $1,525,333.02 | |
| 8/30/2016 | Peter Ferola | General Counsel | Sell | 12,970 | $19.07 | $247,337.90 | |
| 8/25/2016 | Fred Broadway | SVP | Sell | 5,877 | $19.16 | $112,603.32 | |
| 8/25/2016 | Heather C Getz | CFO | Sell | 8,477 | $19.16 | $162,419.32 | |
| 8/25/2016 | Joseph H Capper | Insider | Sell | 38,785 | $19.16 | $743,120.60 | |
| 8/25/2016 | Peter Ferola | General Counsel | Sell | 6,289 | $19.16 | $120,497.24 | |
| 8/24/2016 | George Hrenko | SVP | Sell | 7,473 | $20.11 | $150,282.03 | |
| 8/24/2016 | Heather C Getz | CFO | Sell | 8,778 | $20.11 | $176,525.58 | |
| 8/24/2016 | Joseph H Capper | CEO | Sell | 40,160 | $20.11 | $807,617.60 | |
| 8/24/2016 | Peter Ferola | General Counsel | Sell | 6,512 | $20.11 | $130,956.32 | |
| 8/23/2016 | George Hrenko | SVP | Sell | 3,165 | $20.67 | $65,420.55 | |
| 8/23/2016 | Heather C Getz | CFO | Sell | 3,717 | $20.67 | $76,830.39 | |
| 8/23/2016 | Joseph H Capper | CEO | Sell | 17,008 | $20.67 | $351,555.36 | |
| 8/23/2016 | Peter Ferola | General Counsel | Sell | 2,758 | $20.67 | $57,007.86 | |
| 8/22/2016 | George Hrenko | SVP | Sell | 4,149 | $20.85 | $86,506.65 | |
| 8/22/2016 | Heather C Getz | CFO | Sell | 4,874 | $20.85 | $101,622.90 | |
| 8/22/2016 | Joseph H Capper | CEO | Sell | 22,298 | $20.85 | $464,913.30 | |
| 8/22/2016 | Peter Ferola | General Counsel | Sell | 3,616 | $20.85 | $75,393.60 | |
| 8/19/2016 | Daniel Wisniewski | SVP | Sell | 9,025 | $20.96 | $189,164.00 | |
| 8/19/2016 | Heather C Getz | CFO | Sell | 9,026 | $20.96 | $189,184.96 | |
| 8/19/2016 | Joseph H Capper | Insider | Sell | 9,049 | $20.96 | $189,667.04 | |
| 8/19/2016 | Peter Ferola | General Counsel | Sell | 9,035 | $20.96 | $189,373.60 | |
| 5/9/2014 | Ronald Ahrens | Director | Buy | 6,000 | $7.37 | $44,220.00 | |
| 11/12/2013 | Ronald Ahrens | Director | Buy | 5,000 | $11.73 | $58,650.00 | |
| 11/12/2012 | Ronald A Ahrens | Director | Buy | 15,000 | $2.22 | $33,300.00 | |
| 9/5/2012 | Joseph H Capper | CEO | Buy | 23,540 | $2.25 | $52,965.00 | |
| 8/31/2012 | Joseph H Capper | CEO | Buy | 2,600 | $2.28 | $5,928.00 | |
| 8/29/2012 | Joseph H Capper | CEO | Buy | 10,800 | $2.30 | $24,840.00 | |
| 8/28/2012 | Joseph H Capper | CEO | Buy | 1,300 | $2.19 | $2,847.00 | |
| 8/27/2012 | Joseph H Capper | CEO | Buy | 1,600 | $2.12 | $3,392.00 | |
| 8/23/2012 | Joseph H Capper | CEO | Buy | 9,600 | $2.08 | $19,968.00 | |
| 8/20/2012 | Joseph H Capper | CEO | Buy | 14,160 | $1.97 | $27,895.20 | |
| 8/17/2012 | Joseph H Capper | CEO | Buy | 9,800 | $2.10 | $20,580.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for BioTelemetry (NASDAQ:BEAT)
Latest Headlines for BioTelemetry (NASDAQ:BEAT)
| Source: |
|
| Date | Headline |
|---|
 | BioTelemetry, Inc. (BEAT) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - October 11 at 4:42 PM |
 | Stocks Under Scanner in the Medical Research Space -- Organovo, BioTelemetry, Bruker, and PerkinElmer
www.bizjournals.com - October 10 at 5:42 PM |
 | How Did BioTelemetry Inc’s (BEAT) 39.58% ROE Fare Against The Industry?
finance.yahoo.com - October 6 at 4:43 PM |
| BioTelemetry, Royal Gold, Microsoft and Amazon highlighted as Zacks Bull and Bear of the Day
finance.yahoo.com - October 6 at 4:43 PM |
| Bull of the Day: BioTelemetry (BEAT)
finance.yahoo.com - October 6 at 8:21 AM |
| BioTelemetry: Cramer's Top Takeaways
finance.yahoo.com - October 4 at 1:20 PM |
| Here's Why Mazor Robotics (MZOR) Stock Is Worth a Bet Now
finance.yahoo.com - October 2 at 11:54 AM |
| PAREXEL's Acquisition by Pamplona Approved by Shareholders
finance.yahoo.com - October 2 at 11:53 AM |
| Cramer reviews the bull and bear cases for medical device...
finance.yahoo.com - October 2 at 11:53 AM |
 | Biotelemetry: King Of A Growing Market - Seeking Alpha
seekingalpha.com - September 28 at 12:39 AM |
 | Here's Why You Should Bet on BioTelemetry (BEAT) Stock Now
www.nasdaq.com - September 21 at 4:14 PM |
| XHS's Holdings Imply 15% Gain Potential
www.nasdaq.com - September 21 at 11:48 AM |
| 5 Momentum Stocks Powered by Driehaus Strategy
finance.yahoo.com - September 21 at 11:48 AM |
| Here's Why You Should Bet on BioTelemetry (BEAT) Stock Now
finance.yahoo.com - September 21 at 11:48 AM |
| ETFs with exposure to BioTelemetry, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 9:30 PM |
| BioTelemetry, Inc. – Value Analysis (NASDAQ:BEAT) : September 19, 2017
finance.yahoo.com - September 19 at 9:30 PM |
| BioTelemetry Enters Oversold Territory (BEAT)
www.nasdaq.com - September 18 at 4:49 PM |
| BioTelemetry, Inc. breached its 50 day moving average in a Bearish Manner : BEAT-US : September 18, 2017
finance.yahoo.com - September 18 at 4:49 PM |
| BioTelemetry, Inc. (BEAT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 16 at 4:54 PM |
| Notable Friday Option Activity: LOW, GRA, BEAT - Nasdaq
www.nasdaq.com - September 15 at 9:54 PM |
| Does BioTelemetry Inc’s (BEAT) PE Ratio Warrant A Buy?
finance.yahoo.com - September 15 at 4:50 PM |
| BioTelemetry, Inc. (BEAT) Now Covered by Analysts at Off Wall Street
www.americanbankingnews.com - September 15 at 11:48 AM |
| Can BioTelemetry (BEAT) Run Higher on Strong Earnings Estimate Revisions?
finance.yahoo.com - August 30 at 5:44 PM |
| Signal Genetics (MGEN) vs. BioTelemetry (BEAT) Critical Contrast
www.americanbankingnews.com - August 30 at 12:18 PM |
| Short Interest in BioTelemetry, Inc. (BEAT) Drops By 33.7%
www.americanbankingnews.com - August 29 at 1:06 AM |
| Why Biotelemetry (BEAT) Could Be an Impressive Growth Stock - Nasdaq
www.nasdaq.com - August 23 at 9:37 PM |
| ETFs with exposure to BioTelemetry, Inc. : August 21, 2017
finance.yahoo.com - August 23 at 4:37 PM |
| Why Biotelemetry (BEAT) Could Be an Impressive Growth Stock
finance.yahoo.com - August 23 at 4:37 PM |
| BioTelemetry, Inc. (BEAT) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 22 at 4:36 PM |
| Trump & Terror Hint at Market Pullback: 5 Ultra-Safe Picks - Nasdaq
www.nasdaq.com - August 22 at 2:29 AM |
| Here's Why Investors Should Buy BioTelemetry (BEAT) Now - Nasdaq
www.nasdaq.com - August 22 at 2:29 AM |
| BioTelemetry (BEAT) vs. Signal Genetics (MGEN) Financial Review
www.americanbankingnews.com - August 22 at 12:18 AM |
 | Here's Why Investors Should Buy BioTelemetry (BEAT) Now
www.zacks.com - August 21 at 4:27 PM |
| Trump & Terror Hint at Market Pullback: 5 Ultra-Safe Picks
finance.yahoo.com - August 21 at 4:27 PM |
| Here's Why Investors Should Buy BioTelemetry (BEAT) Now
finance.yahoo.com - August 21 at 4:27 PM |
| BioTelemetry, Inc. (BEAT) Expected to Earn FY2017 Earnings of $1.00 Per Share
www.americanbankingnews.com - August 21 at 5:34 AM |
| Head-To-Head Survey: BioTelemetry (BEAT) vs. Signal Genetics (MGEN)
www.americanbankingnews.com - August 21 at 2:10 AM |
| Head to Head Review: Signal Genetics (MGEN) and BioTelemetry (BEAT)
www.americanbankingnews.com - August 19 at 6:34 AM |
| Equities Analysts Offer Predictions for BioTelemetry, Inc.'s Q3 2017 Earnings (BEAT)
www.americanbankingnews.com - August 18 at 7:20 AM |
| BioTelemetry Hits a 52-Week High: What's Driving the Stock?
www.zacks.com - August 16 at 5:02 PM |
| BioTelemetry Hits a 52-Week High: What's Driving the Stock?
finance.yahoo.com - August 16 at 5:02 PM |
| Equities Analysts Issue Forecasts for BioTelemetry, Inc.'s FY2017 Earnings (NASDAQ:BEAT)
www.americanbankingnews.com - August 11 at 11:18 AM |
| BioTelemetry, Inc. :BEAT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017
finance.yahoo.com - August 10 at 5:38 PM |
| Sidoti Reiterates Buy Rating for BioTelemetry, Inc. (NASDAQ:BEAT)
www.americanbankingnews.com - August 10 at 2:39 PM |
| BioTelemetry (BEAT) Q2 Earnings Top, Revenues Meet Estimates
finance.yahoo.com - August 9 at 4:41 PM |
| Edited Transcript of BEAT earnings conference call or presentation 8-Aug-17 9:00pm GMT
finance.yahoo.com - August 9 at 4:41 PM |
| Dougherty & Co Boosts BioTelemetry, Inc. (BEAT) Price Target to $40.00
www.americanbankingnews.com - August 9 at 1:30 PM |
 | BioTelemetry, Inc. Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 9 at 2:23 AM |
| BioTelemetry, Inc. (NASDAQ:BEAT) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 8 at 9:30 PM |
| BioTelemetry posts 2Q profit
finance.yahoo.com - August 8 at 9:16 PM |
BioTelemetry (BEAT) Chart for Saturday, October, 21, 2017
